Oxford Biomedica plc (OTCMKTS:OXBDF – Free Report) – Investment analysts at Cantor Fitzgerald cut their FY2024 earnings per share estimates for Oxford Biomedica in a research note issued on Tuesday, April 30th. Cantor Fitzgerald analyst R. Bienkowski now anticipates that the company will earn ($0.22) per share for the year, down from their previous estimate of ($0.19). The consensus estimate for Oxford Biomedica’s current full-year earnings is ($0.38) per share.
Oxford Biomedica Price Performance
Shares of OXBDF opened at $3.79 on Friday. Oxford Biomedica has a twelve month low of $2.09 and a twelve month high of $6.02. The stock’s fifty day simple moving average is $2.57 and its 200 day simple moving average is $2.54.
Oxford Biomedica Company Profile
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
See Also
- Five stocks we like better than Oxford Biomedica
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What is the Shanghai Stock Exchange Composite Index?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
